Quick Access

No journals followed

Browse journals

No saved papers

Feed Explore Trending Questions Researchers

⌘K

QLS5132 Goes after CLDN6 in Ovarian Cancer | Synapse

April 24, 2026

QLS5132 Goes after CLDN6 in Ovarian Cancer

Key Points

The research aims to assess the effectiveness of QLS5132 in treating advanced platinum-resistant ovarian cancer.
Conducted a phase I clinical trial
Evaluated safety and activity of QLS5132
Targeted CLDN6 in ovarian cancer patients
QLS5132 demonstrates a favorable safety profile
Preliminary data suggests activity against ovarian cancer
Encouraging outcomes in advanced cancer cases

Abstract

For patients with advanced platinum-resistant ovarian cancer, treatment options remain limited, but new agents are emerging. One is QLS5132, an antibody-drug conjugate targeting CLDN6; early data from a phase I trial indicates that it has a favorable safety profile and appears active in this disease.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...

Cite this study

A Tue, study studied this question.

www.synapsesocial.com/papers/69eb0ac4553a5433e34b4bec — DOI: https://doi.org/10.1158/2159-8290.cd-nw2026-0044

Journals

Cancer Discovery

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...